Pharmacogenetics of RAS-affecting AGT and ACE variants and the efficacy of Valsartan/HCTZ therapy.

The AGT rs5050 variant remained highly significant for both SBP (AC: B = 13.91, 95% CI: 9.63–18.19, p < 0.001; CC: B = 15.18, 95% CI: 6.40–23.95, p < 0.001) as shown in Table 2 , and DBP (AC: B = 10.49, 95% CI: 7.75–13.22, p < 0.001; CC: B = 7.15, 95% CI: 1.55–12.76, p = 0.013).

also in 132,142 other papers

In contrast, AGT rs5051, ATG rs699, and AGT rs4762 demonstrated no statistically significant associations with SBP or DBP changes after multivariate adjustment, despite some nominally significant findings observed in unadjusted (crude) analyses.

also in 7,732 other papers